Use access key #2 to skip to page content.

Recs

2

Delcath (DCTH) deflates 40% Premarket

February 22, 2011 – Comments (0) | RELATED TICKERS: DCTH

Delcath is down significantly today following the FDA's refusal to file the NDA and request for additional information. It seems to do with the manufacturing aspect of it. The euro approval is still on track. Much more informed biotech investors have recommended this one recently and i added some premarket to take advantage of it.   [more]

Blog Archive

2011
February (1)

Featured Broker Partners


Advertisement